AbbVie Remains Confident About Rinvoq Despite Coming Safety Labeling Update
Executive Summary
A safety-related FDA revision of Rinvoq’s label in rheumatoid arthritis is a perceived threat to the JAK inhibitor’s growth, but it and fellow immunology asset Skyrizi produced another strong sales quarter.
You may also be interested in...
AbbVie Grows Gastrointestinal Business With Rinvoq Approval In UC
Along with Skyrizi’s expected approval in Crohn’s, AbbVie says Rinvoq in ulcerative colitis is key to its Humira sales erosion strategy. It is Rinvoq’s third US supplemental approval since December.
Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.
Dermatology To Become A Key Franchise For Incyte
Having just launched Opzelura in the US for atopic dermatitis, the US biotech is hoping for another approval in the next few months for its topical JAK inhibitor, this time for vitiligo.